­First patient dosed in IDE397 combination with pemetrexed, representing a novel and potential first-in-class combination in MTAP-deletion tumors First patient dosed in IDE397 combination with taxane ...

ERAS-007, a potential best-in-class ERK1/2 inhibitor, will be evaluated initially in combinations that could address over half of patients with colorectal cancer SAN DIEGO, Sept. 22, 2021 (GLOBE ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...

(ORLANDO, Dec. 9, 2025) Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed ...

At the World Economic Forum in Davos, Switzerland, earlier this month, experts cautioned that by 2050, as many as 10 million people a year could die from drug-resistant bacteria, viruses, and other ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...